Inflammatory Markers During Early Treatment of Seroconverters in a Randomized Placebo-Controlled Trial of PrEP (ANRS-IPERGAY)-Reference-Cited by-同舟云学术

Inflammatory Markers During Early Treatment of Seroconverters in a Randomized Placebo-Controlled Trial of PrEP (ANRS-IPERGAY)

Published:2021-03-01 Issue:3 Volume:8 Page:
ISSN:2328-8957
Container-title:Open Forum Infectious Diseases
language:en
Short-container-title:

Author:

Chawki Sylvain¹²^ORCID,Charreau Isabelle³,Gabassi Audrey¹²,Carette Diane³,Cua Eric⁴,Cotte Laurent⁵,Pialoux Gilles⁶,Pintado Claire⁷,Meyer Laurence³,Chaix Marie-Laure¹²,Delaugerre Constance¹²,Molina Jean-Michel⁷²

Affiliation:

1. Department of Virology, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France

2. INSERM U944, Paris University, Paris, France

3. INSERM SC10-US19, Villejuif, France

4. Maladies Infectieuses, Hôpital L’Archet, Nice, France

5. Maladies Infectieuses, Hospices Civils de Lyon, Hôpital de la Croix-Rousse, Lyon, France

6. Maladies Infectieuses, Hôpital Tenon, Assistance Publique Hôpitaux de Paris, Paris, France

7. Maladies Infectieuses, Hôpital Saint-Louis, Assistance Publique Hôpitaux de Paris, Paris, France

Abstract

Abstract HIV-related inflammation is associated with poor outcomes. We describe inflammatory biomarkers in 17 participants in a pre-exposure prophylaxis trial who seroconverted with very early initiation of antiretroviral therapy. Inflammation peaked at the time of HIV infection and returned to baseline within 6–12 months. Starting antiretroviral therapy very early could help mitigate long-lasting HIV-related inflammation.

Funder

National Agency of Research on AIDS and Viral Hepatitis

Bill and Melinda Gates Foundation

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Oncology

Link

http://academic.oup.com/ofid/advance-article-pdf/doi/10.1093/ofid/ofab085/36649015/ofab085.pdf

Reference12 articles.

1. Long-term therapeutic impact of the timing of antiretroviral therapy in patients diagnosed with primary human immunodeficiency virus type 1 infection;Novelli;Clin Infect Dis,2018

2. Pre-therapy inflammation and coagulation activation and long-term CD4 count responses to the initiation of antiretroviral therapy;Achhra;HIV Med,2015

3. Prevention of HIV-1 infection with early antiretroviral therapy;Cohen;N Engl J Med,2011

4. Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections;Stacey;J Virol,2009

5. Persistent, albeit reduced, chronic inflammation in persons starting antiretroviral therapy in acute HIV infection;Sereti;Clin Infect Dis,2017